NASDAQ · ACET
Healthcare · Biotechnology
$5.74
Down-$0.44 (-7.12%)
Updated Oct 9, 2026, 3:53 AM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ACET
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
ACET closed at $5.74 after 21 trading sessions, down 39.77% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $6.16 | $6.17 | $5.5501 | $5.74 | 487.86K |
| Oct 7, 2026 | $6.21 | $6.44 | $6.12 | $6.18 | 214.3K |
| Oct 6, 2026 | $6.52 | $6.55 | $6.21 | $6.25 | 135.72K |
| Oct 5, 2026 | $6.53 | $6.69 | $6.28 | $6.47 | 152.77K |
| Oct 2, 2026 | $6.70 | $6.8199 | $6.50 | $6.50 | 164.98K |
| Oct 1, 2026 | $7.06 | $7.17 | $6.64 | $6.64 | 149.04K |
| Sep 30, 2026 | $6.80 | $7.2799 | $6.71 | $7.14 | 211.06K |
| Sep 29, 2026 | $6.41 | $7.06 | $6.37 | $6.83 | 668.2K |
| Sep 28, 2026 | $7.96 | $7.96 | $6.25 | $6.35 | 2.15M |
| Sep 25, 2026 | $8.29 | $9.11 | $8.29 | $9.02 | 638.6K |
| Sep 24, 2026 | $8.49 | $8.49 | $7.89 | $8.27 | 358.55K |
| Sep 23, 2026 | $9.12 | $9.3106 | $8.42 | $8.49 | 263.25K |
| Sep 22, 2026 | $9.00 | $9.44 | $8.981 | $9.145 | 87.83K |
| Sep 21, 2026 | $9.23 | $9.24 | $8.782 | $8.93 | 49.79K |
| Sep 18, 2026 | $8.96 | $9.405 | $8.76 | $9.18 | 114.53K |
| Sep 17, 2026 | $9.20 | $9.33 | $8.86 | $9.01 | 130.68K |
| Sep 16, 2026 | $8.52 | $9.44 | $8.445 | $9.05 | 258.21K |
| Sep 15, 2026 | $9.70 | $9.70 | $7.905 | $8.505 | 479.24K |
| Sep 14, 2026 | $9.51 | $9.84 | $9.42 | $9.70 | 124.76K |
| Sep 11, 2026 | $9.65 | $9.80 | $9.38 | $9.52 | 119.5K |
| Sep 10, 2026 | $9.46 | $9.68 | $9.31 | $9.53 | 119K |
The latest Smart Investors Daily articles mentioning ACET.
Company
Market Activity
Research & News
ACET research
Company profile and research snapshot.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 29, 2026 | Wedbush | Outperform | — |
| Sep 28, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 18, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 6, 2026 | Guggenheim | Buy | — |
| Mar 23, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 3, 2026
Adicet Bio (NASDAQ:ACET) reported positive clinical data for prula-cel, its investigational allogeneic gamma delta CAR-T cell therapy, in patients with systemic lupus erythematosus, or SLE, including patients with lupus nephritis. The company said that, among evaluable lupus nephritis patients, 50%
SeekingAlpha · Sep 30, 2026
2026-09-30. The following slide deck was published by Adicet Bio, Inc.
Benzinga · Sep 29, 2026
Wedbush analyst Robert Driscoll maintains Adicet Bio (NASDAQ:ACET) with a Outperform and raises the price target from $25 to $28.
Yahoo · Sep 28, 2026
Adicet Bio (NASDAQ:ACET) reported 12-month DORIS remission in 54% of evaluable systemic lupus erythematosus patients and complete renal response in 50% of evaluable lupus nephritis patients, supporting plans to begin pivotal study start-up activities in the fourth quarter of 2026. Key Investor TakeawaysAdicet Bio (NASDAQ:ACET) reported positive prula-cel Phase 1 lupus data from 22 efficacy-evaluable patients, including 16 with lupus nephritis and six with extra-renal SLE.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ACET.
No results
No recent SID articles mention ACET.
